SKI Market

Indian Indices

Nifty

25,461.00 55.70
(0.22%)

Sensex

83,432.89 193.42
( 0.23%)

Bank Nifty

57,031.90 239.95
( 0.42%)

Nifty IT

39,166.55 312.25
( 0.80%)

Global Indices

Nasdaq

44,849.54 344.11
(0.77%)

Dow Jones

6,298.76 50.34
(0.81%)

Hang Seng

39,792.23 6.33
(0.02%)

Nikkei 225

8,822.91 -0.29
(0.00%)

Forex

USD-INR

85.63 0.05
(0.05%)

EUR-INR

100.93 0.01
(0.01%)

GBP-INR

117.11 -0.50
(-0.43%)

JPY-INR

0.60 0.00
(-0.16%)

YOU ARE HERE :
HOME
Markets
Equity
Hot Pursuit - Detailed News

EQUITY - MARKET SCREENER

Back

Lupin launches generic version of anticholinergic medication Ipratropium bromide in United States

04-Jul-25 15:29 Hrs IST

Ipratropium Bromide Nasal Solution is a bioequivalent to Atrovent Nasal Sprayof Boehringer Ingelheim Pharmaceuticals, Inc.

The solution is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children aged 6 years and older.

According to IQVIA MAT May 2025, Ipratropium Bromide Nasal Solution (RLD Atrovent) had estimated annual sales of $63 million in the U.S.

Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

The company's consolidated net profit surged 114.9% to Rs 772.52 crore on a 13.6% jump in net sales to Rs 5,562.20 crore in Q4 FY25 over Q4 FY24.

The scrip added 1.36% to end at Rs 1982.20 on the BSE today.

25,461.00 55.70 (0.22%)

83,432.89 193.42 ( 0.23%)

57,031.90 239.95 ( 0.42%)

39,166.55 312.25 ( 0.80%)

44,849.54 344.11 (0.77%)

6,298.76 50.34 (0.81%)

39,792.23 6.33 (0.02%)

8,822.91 -0.29 (0.00%)

85.63 0.05 (0.05%)

100.93 0.01 (0.01%)

117.11 -0.50 (-0.43%)

0.60 0.00 (-0.16%)